Cancer is a disease of unscheduled cell division and many anticancer drugs target the cell cycle to inhibit the proliferation of cancer cells. We conducted a screen for new anticancer drugs that induce cell cycle arrest using a small compound library. From this screen, we identified 2-(3-methyl-thiophen-2-yl)-4-(3,4-dioxybenzene) thiazole (MTBT), which causes accumulation of cancer cells with 4N DNA content and inhibits colony formation of several cancer cell lines. We further showed that the treatment of cancer cells with this compound for a longer time period leads to apoptosis, as indicated by the presence of cells with a sub-G 1 peak and the appearance apoptotic markers. The increased phosphorylation of serine 10 on histone H3 in MTBT-treated cancer cells suggests cell cycle arrest in the M-phase. Strikingly, MTBT-induced cell cycle arrest and enhanced H3 (Ser10) phosphorylation are abrogated by the pretreatment with SB203580, a specific inhibitor of mitogen-activated protein kinase p38. Moreover, treatment of cancer cells with MTBT induces the phosphorylation of p38, indicative of p38 activation. Together, we have identified a new compound that inhibits cancer cell proliferation, which is likely a consequence of p38 activation.
Introduction
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine kinases that transmit various extracellular stimuli to the nucleus [1, 2] . p38, a member of the MAPK family, is activated in response to a wide range of extracellular stress stimuli, such as hyperosmolarity, heat shock, genotoxic stresses, UV light, g-irradiation, metabolic stress, and protein synthesis inhibition [3] [4] [5] [6] . In human cells, four genes encode p38 MAPK family members, p38a, p38b, p38g, and p38d. Although both p38a and p38b are expressed ubiquitously, p38b is expressed at very low levels. Previous work has shown that p38g and p38d are only expressed in certain types of tissue, indicating their specialized functions [7] . Accumulating evidence supports the role of p38a as a tumor suppressor on the basis of its negative role in cell cycle progression and the induction of apoptosis.
p38a negatively regulates cell cycle progression at both G 1 to S and G 2 to M transitions. The downstream targets include cyclins, cyclin-dependent kinase regulators, and tumor suppressor p53 [8] . Recent evidence shows that the activation of the p38 MAPK pathway delays the G 2 to M transition by destabilizing Cdc25B, a phosphatase required to activate cyclin-dependent kinase [9, 10] . Previous data also show that the introduction of activated recombinant p38 is able to induce mitotic arrest, but p38-specific inhibitors can abrogate cell cycle arrest when the integrity of the mitotic spindle is compromised [11] . Moreover, p38 activation is involved in the induction of apoptosis by different cellular stresses and the apoptotic effect of p38 might be mediated by the activation of p53 and caspase [12] . Thus, activation of p38 could play a critical role in cancer treatment.
Recent studies indicate that p38 MAPK activation is necessary for the killing of cancer cells by a variety of anticancer agents. HeLa cells treated with microtubuledepolymerizing reagents (nocodazole, vincristine, and vinblastine) or a microtubule-stabilizing compound (taxol) show M-phase arrest and cell death. p38 activation is observed in these treated cells and this activation is necessary for the cell death induced by chemotherapeutic drugs [13] . Cisplatin and doxorubicin are widely used in cancer chemotherapy and treatment with these drugs leads to increased p38 activation as indicated by its phosphorylation [14] . However, recent studies have shown that nocodazole inhibits p38 activation induced by UV treatment [15] . The discrepancy in the previous reports could be a result of the different methods or cell lines used for the assessment of p38 activity. Therefore, the role of p38 in cancer treatment needs to be re-evaluated.
We are interested in the isolation of new anticancer drugs that target cell cycle progression. From a small molecule library, we identified a new compound, 2-(3-methylthiophen-2-yl)-4-(3,4-dioxybenzene) thiazole (MTBT), which causes cell cycle arrest and apoptosis, as evidenced by the accumulation of cancer cells with 4N DNA content and the increase in the number of cells positive for apoptotic markers. Enhanced H3 (Ser10) phosphorylation in MTBT-treated cells indicates cell cycle arrest in the M-phase. The results of the colony-formation assay demonstrate the anticancer activity of MTBT. Strikingly, MTBT-induced cell cycle arrest and H3 (Ser10) phosphorylation were abrogated when the cells were pretreated with a specific inhibitor for p38. Consistently, the phosphorylation of p38 increased shortly after the cells were treated with MTBT. Therefore, we have identified a new anticancer compound that inhibits cancer cell growth, and this inhibition is likely a consequence of p38 activation.
Materials and methods

Cells and growth
The cell culture media and fetal bovine serum (FBS) were purchased from Hyclone (HyClone Laboratories Inc., Logan, Utah, USA). The cell lines were obtained from the Cell Culture Centre, Institute of Basic Medical Science at the Chinese Academy of Medical Sciences (Beijing, China).
A549 cells (human non-small-cell lung cancer) were maintained in Ham's F-12 medium supplemented with 10% FBS. HepG2 cells (human hepatoma cells) were grown in minimum essential medium containing 10% FBS. HeLa cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS. Cells were incubated at 371C in a humidified incubator containing 5% CO 2 .
Chemicals
MTBTwas purchased from Enamine Ltd (Kiev, Ukraine). The compounds used for screening were dissolved in dimethyl sulfoxide (DMSO) at 10 mg/ml as stock solution. The p38 MAPK inhibitor SB203580 and DMSO were purchased from Sigma (Shanghai, China).
Colony-formation assay
Cells were plated in six-well plates at 1000 cells/well and incubated for 24 h. After treatment with MTBT for 24 h, MTBTwas washed off with fresh medium and the cells were further incubated for 14 days. Thereafter, the cells were washed with cold PBS, fixed with ice-cold methanol for 10 min, and stained with 10% Giemsa for 2 min. The cells were examined under a microscope and the colony-formation efficiency was calculated using the following formula: colonyformation rate(%) = colony number/1000 Â 100%.
FACS analysis
A549 cells in the exponential growth phase were treated with MTBT or 0.1% DMSO (control). Cells were harvested by trypsin digestion followed by centrifugation. After washing with cold PBS (1 Â ), the cells were resuspended in ice-cold 70% ethanol at 41C for at least 30 min. The fixed cells were then collected by brief centrifugation and resuspended in PBS containing RNase A (Sigma, St Louis, Missouri, USA) and propidium iodide (PI; Sigma). After incubation for 30 min at room temperature, the samples were subjected to cell cycle analysis using fluorescence-activated cell sorting (FACS) .
To analyze the phosphorylation of Ser10 of histone H3 and p38 MAPK, cells were first washed with cold PBS (1 Â ) and then fixed in 4% paraformaldehyde at room temperature for 40 min. After washing with PBS, cells were blocked in 1 Â PBS plus 0.5% FBS and 0.2% Tween X-100 for 10 min at 41C. The cells were then incubated with monoclonal phospho-H3 (Ser10) antibodies or phosphop38 MAPK (Thr180/Tyr182) antibodies (1 : 40 dilution; Cell Signaling Technology, Danvers, Massachusetts, USA) for 2 h at room temperature, followed by fluorescein isothiocyanate (FITC)-conjugated secondary antibodies (1 : 100 dilution) for 1 h at room temperature. The cells incubated only with FITC-conjugated secondary antibodies were used as a negative control. The fluorescence signals were detected by FACS. The relative fluorescence intensity (FI) after MTBT treatment was calculated using the following formula:
To analyze the cell cycle distribution of A549 cells, the cells stained with monoclonal phospho-H3 (Ser10) antibodies and FITC-conjugated secondary antibodies (1 : 100 dilution) were incubated with PI for 30 min at room temperature and then subjected to FACS analysis.
FITC-annexin V/PI apoptosis assay A549 cells were either treated with 0, 2.16, 4.32, and 8.64 mmol/l MTBT for 24 h, or with 8.64 mmol/l MTBT for 24, 48, and 72 h. The treated cells were harvested, washed three times with 1 Â PBS, and resuspended in 500 ml binding buffer [10 mmol/l HEPES/sodium hydroxide (pH7.4), 140 mmol/l sodium chloride, and 2.5 mmol/l CaCl 2 ]. Thereafter, 5 ml FITC-labeled annexin V (Zhongshan JinQiao Biotechnology Ltd., Beijing, China) was added and the cells were incubated in the dark for 10 min. We added 5 ml of PI (10 mg/ml in binding buffer) to each sample before FACS analysis.
Western-blotting analysis A549 cells were incubated with or without 4.32 mmol/l MTBT for 1, 3, 5, and 12 h. The cells were washed twice with cold 1 Â PBS, lysed in RAPI buffer (Applygen Technologies Inc., Beijing, China) for 30 min, and centrifuged at 14 000 rpm for 20 min at 41C. We separated 5 ml of total protein (5 mg/ml) on 10% SDS-PAGE gels and transferred the proteins onto polyvinylidene difluoride membranes. After blocking with 5% (w/v) nonfat dry milk in tris-buffered saline containing 0.2% Tween-20 for 1 h, the membranes were incubated with monoclonal phospho-p38 MAPK (Thr180/Tyr182) antibodies or p38 MAPK antibodies (1 : 1000 dilution; Cell Signaling Technology) for 2 h and then with peroxidase-conjugated secondary antibodies for 1 h. The protein bands were detected using the ECL system (Alpha Innotech Corporation, San Leandro, California, USA). The level of b-actin was used as a loading control.
Results
MTBT inhibits proliferation of cancer cells
We are interested in the isolation of new anticancer drugs that target cell cycle progression. For this purpose, we used the MTT assay to measure the viability loss of cancer cells after treatment with compounds from a small molecule library (10 000 compounds). Among the 10 000 compounds from this library, about 80 show anticancer activity at 2 mg/ml and they were selected for further analysis. We found one compound, MTBT, that caused more than 50% viability loss of A549, HeLa, and HepG2 cancer cells at 2 mg/ml. MTBT is a new compound without any reported bioactivity, and the structure of this compound is shown in Fig. 1a . We further used a colonyformation assay to evaluate the inhibitory effect of MTBT on cancer cell proliferation. Cells were inoculated in sixwell plates at a density of 1000 cells/well, cultured for 24 h, and then treated with various concentrations of MTBT for 24 h. After MTBT washout, we incubated the cells in fresh medium without MTBT for 14 days to assess colony formation. Compared with that after treatment with DMSO, the colony formation of A549, HeLa, and HepG2 cells was inhibited significantly after treatment with 4.3 mmol/l MTBT. Stronger inhibition of colony formation was observed in cells treated with higher concentrations of MTBT (Fig. 1b) . Therefore, we isolated a new compound, MTBT, that inhibits cancer cell proliferation and prevents colony formation of several cancer cell lines.
MTBT triggers cell cycle arrest in A549 cells
We next asked whether MTBT inhibits cancer cell growth by targeting cell cycle progression. For this purpose, A549 cells were first incubated for different amounts of time in the presence of MTBT at various concentrations, which was followed by FACS analysis. After treatment with MTBT, we observed accumulation of A549 cells with 4N content of DNA, indicative of a G 2 /M arrest ( Table 1 
MTBT induces apoptosis in A549 cells
The induction of apoptosis is a common mechanism for many anticancer drugs; thus, we examined the apoptotic process in MTBT-treated cells. A549 cells were first incubated with MTBT at various concentrations for different amounts of time and then subjected to annexin V-FITC labeling and PI staining as described in the Materials and Methods section. We used FACS analysis to determine the proportion of A549 cells positive for annexin V-FITC, PI, or both. The positivity of A549 cells for FITC or for both FITC and PI indicate that they are in early or late apoptotic stages, respectively. After treatment with different concentrations of MTBT for 24 h, we noticed a clearly increased population of Fig. 3a) . Moreover, we examined apoptosis in cells treated with 8.64 mmol/l MTBT for different time periods. The proportion of apoptotic cells increased from 11.65% (5.51 + 6.14) at 24 h to 55.31% (53.42 + 1.89) at 72 h (Table 2 , Fig. 3b ). In addition, the accumulation of cells positive for both PI and FITC became more significant after longer treatment with MTBT, which indicates the increase of cells in late apoptotic stages.
All these results suggest that MTBT also induces apoptosis in a dose-dependent and time-dependent manner.
MTBT induces M-phase arrest
The Ser10 of histone H3 on condensed chromosomes is highly phosphorylated by aurora B kinase during mitosis, thus H3 (Ser10) phosphorylation has been used as a sensitive marker for mitotic cells [16, 17] . To determine whether the accumulation of cells with 4N DNA content is a consequence of mitotic arrest, we analyzed H3 (Ser10) phosphorylation in MTBT-treated cells. A549 cells were first cultured with 4.32 and 8.64 mmol/l MTBT for 24 h and then probed with a phospho-antibody specific for H3 (Ser10). After incubation with FITCconjugated secondary antibodies and DNA dye (PI), the cells were subjected to FACS analysis to determine H3 (Ser10) phosphorylation and DNA content. Compared with untreated cells, treatment with 4.32 and 8.64 mmol/l MTBT caused a 2.12-and 2.18-fold increase in the phosphorylation of H3 (Ser10), respectively (Fig. 4a) . We found that more cells with 4N DNA content became positive for H3 (Ser10) phosphorylation. Only 4.62% of untreated cells that showed 4N DNA content were positive for H3 (Ser10) phosphorylation, but the treatment with 4.32 and 8.64 mmol/l MTBT increased the number to 37.9 and 28.7%, respectively (Fig. 4b) . It is surprising that we did not see dose-dependent accumulation of cells with 4N content of DNA. We speculate that some arrested cells underwent apoptosis, and this speculation is supported by the appearance of a sub-G 1 peak in some cells after treatment with higher concentrations of MTBT (Fig. 2) . Therefore, treatment with MTBTcauses cell cycle arrest in the M-phase, which may contribute to the anticancer activity of this compound.
Functional p38 MAPK is required for MTBT-induced cell cycle arrest
Previous studies have confirmed that MAPKs elicit the rapid phosphorylation of Ser10 on H3 [18] . The use of specific MAPK inhibitors enables the dissection of the role of different MAPK pathways in H3 phosphorylation. SB203850, a specific inhibitor of p38 MAPK, has been shown to block H3 (Ser10) phosphorylation induced by a protein synthesis inhibitor [19] . Therefore, we tested whether MTBT-induced cell cycle arrest requires the activity of p38. For this purpose, we examined MTBTinduced cell cycle arrest in cells pretreated with the p38 inhibitor SB203580. A549 cells were first incubated with 50 or 100 mmol/l SB203580 for 2 h, followed by treatment with 4.32 mmol/l MTBT. After further incubation for 18 h, the cells were collected and analyzed for cell cycle distribution by FACS analysis. In the absence of pretreatment with the p38 inhibitor, MTBT induced significant accumulation of cells with 4N DNA content. In clear contrast, pretreatment with 50 or 100 mmol/l SB203580 blocked the cell cycle arrest induced by MTBT, as evidenced by the decrease in the 4N DNA peak (Fig. 5a ). We found that 66.63% of A549 cells showed 4N DNA content after exposure to 4.32 mmol/l MTBT, but pretreatment with 50 and 100 mmol/l p38 inhibitor lowered the numbers to 25.36 and 17.96%, respectively. Cells treated with p38 inhibitor alone did not show an increased 4N DNA peak (Table 3) .
Previous studies have suggested that disruption of microtubules impairs the activation of p38 induced by DNA damage [20, 21] . However, several groups have shown that microtubule-interfering agents stimulate the activation of the MAPK superfamily, including p38 in certain cell contexts [22] [23] [24] [25] [26] . As we showed that MTBTinduced G 2 /M arrest depends on functional p38, it is possible that mitotic arrest induced by other drugs is also p38 dependent. Thus, we tested whether p38 is required for the cell cycle arrest induced by microtubule disruption under our experimental conditions. Nocodazole is a microtubule-depolymerizing agent, and it has been widely used to disrupt the spindle structure and induce G 2 /M arrest. After exposure to 0.13 mmol/l nocodazole for 18 h, 83.25% of A549 cells showed 4N DNA content, suggesting mitotic arrest. Pretreatment with 50 and 100 mmol/l p38 inhibitor, SB203580, lowered the number to 73.76 and 58.21%, respectively (Table 3 , Fig. 5a ), which is much less significant compared with the suppression of MTBT-induced G 2 /M arrest by the p38 inhibitor. Vincristine is another microtubule-depolymerizing agent that causes G 2 /M arrest. We found that suppression of vincristine-induced cell cycle arrest in A549 cells by SB203580 was not significant either (data not show).
In contrast to nocodazole and vincristine, the anticancer drug taxol stabilizes microtubules, which also leads to G 2 /M arrest. After exposure to 0.03 mmol/l taxol for 18 h, 72.56% of A549 cells showed 4N DNA content, indicating G 2 /M arrest. Pretreatment with 50 and 100 mmol/l of the p38 inhibitor SB203580 lowered the number to 67.61 and 57.77%, respectively (Table 4 , Fig. 5a ). Thus, compared with suppression of MTBT-induced G 2 /M arrest in A549 cells, the suppression of nocodazole-induced or taxolinduced G 2 /M arrest by p38 inhibitor is much less efficient. This discrepancy suggests that MTBT likely induces cell cycle arrest through a mechanism different from that adopted by microtubule-interfering agents.
As phosphorylation of H3 (Ser10) occurs in mitotic cells, we also examined whether pretreatment with the p38 inhibitor suppresses MTBT-induced H3 (Ser10) phosphorylation. As described above, treatment of A549 cells with 4.32 mmol/l MTBT induced clear phosphorylation of Ser10 on H3, but this modification was abolished completely by pretreatment with 50 mmol/l SB203580 for 2 h. Compared with untreated cells, A549 cells treated with 4.32 mmol/l MTBT showed a 2.32-fold increase in H3 (Ser10) phosphorylation (Fig. 5b ), but the increase was barely detected in cells pretreated with the p38 inhibitor (1.01-fold). After treatment with 4.32 mmol/l MTBT, 32.9% of cells showed 4N DNA content and these cells were also positive for H3 (Ser10) phosphorylation, but pretreatment with the p38 inhibitor lowered the number to 3.67% (Fig. 5c) . Therefore, pretreatment of A549 cells with a p38 inhibitor blocks MTBT-induced cell cycle arrest at the M-phase.
MTBT induces the activation of p38 MAPK
The family of p38 MAPKs is activated by dual phosphorylation in the TGY motif of the activation loop [27] . To further determine whether MTBT treatment triggers the phosphorylation of p38, we examined the phosphorylation status of p38 MAPK in A549 cells treated with MTBT. A549 cells treated with 4.32 mmol/l MTBTwere collected at 0, 1, 5, and 12 h. The cells were probed with phospho-p38 MAPK (Thr180/Tyr182) antibodies and FITC-conjugated secondary antibodies for FACS analysis. Compared with untreated cells, cells treated with 4.32 mmol/l MTBT for 1, 5, and 12 h showed a 1.98-, 1.76-, and 1.86-fold increase in p38 phosphorylation, respectively. A substantial increase in p38 phosphorylation was detected in cells treated with MTBT only for 1 h, but further incubation with MTBT did not enhance this phosphorylation (Fig. 6a) . Western-blotting results further confirm the induction of p38 phosphorylation by MTBT (Fig. 6b) . Therefore, treatment with MTBT likely triggers immediate p38 phosphorylation and activation, supporting the possibility that mitotic arrest induced by MTBT treatment is secondary to p38 activation.
Discussion
Most of the anticancer drugs target the cell cycle machinery to block cell division, and we are interested in the isolation of new anticancer drugs that arrest the cell cycle. From the small molecule library [28] , we identified MTBT, a new compound that causes cell cycle arrest and accumulation of cells with 4N DNA content. The increased phosphorylation of Ser10 on histone H3 indicates mitotic arrest. Moreover, treatment of cancer cells with MTBT for a longer time period (24 h) induces apoptosis. Interestingly, MTBT-induced M-phase arrest and the increase in H3 (Ser10) phosphorylation can be alleviated by pretreatment with a p38 inhibitor. Further, we showed that the phosphorylation of p38 increased significantly after MTBT treatment. Although the microtubule-depolymerizing agent nocodazole also induces cell cycle arrest at the M phase, we found that the p38 inhibitor was unable to alleviate nocodazole-induced arrest. Therefore, we identified a new anticancer drug that arrests the cell cycle in the M-phase. This arrest is likely a consequence of p38 activation, but it remains to be determined whether MTBT activates p38 directly.
MTBT is a derivative of 2,4-two-aryl-thiazole, without any anticancer activity reported. Thiazol has a heterocyclic ring and is widely used in anticancer drug development. Many natural chemotherapeutic agents containing a thiazol moiety have been discovered and studied, such as tiazofurin, distamycin, and netropsin [29] [30] [31] . Some thiazol derivatives inhibit the growth of cancer cells by distinct mechanisms, such as inhibition of an essential cytoplasmic purine metabolic enzyme inosine monophosphate dehydrogenase, which is the rate-limiting enzyme for de-novo synthesis of guanosine nucleotides, induction of DNA damage, and inhibition of the activity of topoisomerase II and tyrosine kinase [29] [30] [31] [32] [33] [34] . Here, we showed that a derivative of thiazol, MTBT, blocks the cell cycle in the M-phase likely by activating p38 MAPK. In addition to carrying out further investigation on the anticancer mechanism of MTBT, we will also synthesize new compounds based on the structure of MTBT to find more efficient anticancer derivatives.
Conclusion
We found a new compound, MTBT, that inhibits the proliferation of several cancer cell lines by inducing Mphase arrest and apoptosis. The activation of p38 MAPK is likely responsible for the cell cycle arrest and apoptosis. Our data also show that MTBT can inhibit colony formation of several cancer cell lines, indicating the potential for cancer therapy. Our future interest is to define the direct target of this compound, synthesize more efficient anticancer derivatives using MTBT as the lead compound, and evaluate the in-vivo anticancer activity of this compound using animal models. 
